FDA Cancer Drug Approvals in 2017

All 9 patients in a phase 1 trial testing a neoantigen-targeting personalized cancer vaccine in renal cell carcinoma had no recurrence at data cutoff.

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Julie M. Vose, MD, MBA, discussed MZL research and future directions in the February Letter to Readers.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

The safety profile of pembrolizumab plus neoadjuvant chemotherapy was consistent with the known profiles for each treatment.